Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioaffinity Technologies WT (BIAFW)

Bioaffinity Technologies WT (BIAFW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 6,160 K
  • Annual Income, $ -14,910 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2203 +151.93%
on 03/09/26
0.6000 -7.50%
on 03/17/26
+0.3150 (+131.25%)
since 02/23/26
3-Month
0.2201 +152.16%
on 01/14/26
0.6000 -7.50%
on 03/17/26
+0.2250 (+68.18%)
since 12/17/25
52-Week
0.0525 +957.14%
on 08/21/25
0.8121 -31.66%
on 10/10/25
+0.2650 (+91.38%)
since 03/20/25

Most Recent Stories

More News
New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

CyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung “Unlikely Malignancy” result supported...

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung test Number...

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program...

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Research...

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure ...

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)
Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study

Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters ...

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company’s noninvasive CyPath ® Lung diagnostic test

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034 Precision Pathology Laboratory Services meets...

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced...

BIAF : 4.73 (+73.26%)
BIAFW : 0.5550 (+63.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.